Polo like kinase Plk 1

Polo-like kinase (Plk) is an important cell cycle regulatory kinase that has been implicated in a multitude of cell cycle events. Plks form a family of four different proteins that regulates many as...

MAP kinase kinase MEK Inhibitors

The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death.  The MAPK pathway has emerged as the crucial route between membrane-bound Ras...

Bcr Abl and Src Kinase Inhibitors

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t...

Checkpoint kinase 1 CHK 1

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumo...

Kinases Raf Inhibitors

The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or...

Pfizer's crizotinib given pre-launch to some patients in Japan

In an unusual move, Pfizer's first-in-class drug crizotinib has been made available to a small group of lung cancer sufferers in Japan ahead of its official launch. The oral anaplastic lymphoma kinas...

Pfizer's crizotinib superior to chemotherapy in improving PFS in ALK-positive NSCLC

Pfizer has reported Phase III trial data showing that its anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) is superior to standard chemotherapy in improving progression-free survival (P...

Astex Pharmaceuticals commences Phase 2 non-small cell lung cancer study

Small-molecule therapeutics company Astex Pharmaceuticals, Inc has initiated a Phase 2 clinical trial evaluating HSP90 inhibitor AT13387 in anaplastic lymphoma kinase positive (ALK+) non-small cell lu...

For ALK-Positive Lung Cancer, Phase III Trial Shows Crizotinib Superior To Single-Agent Chemotherapy

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researcher...

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted cond...

Crizotinib reduces tumor size in patients with ALK positive lung cancer

(American Society for Radiation Oncology) Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase positive non-small cell lung cancer, a cancer common...

New diagnostic assay for screening ALK fusions in non-small cell lung carcinoma

Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for trea...

Different Approach Suggested After Progression In NSCLC Patients

Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutati...

Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen.

Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers. Crizo...

Crizotinib.

In August 2011 crizotinib (Xalkori; Pfizer), a small-molecule kinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metasta...

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK).

Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of 3 (...

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

Mutations in the kinase domain of Anaplastic Lymphoma Kinase (ALK) have recently been shown to be important for the progression of the childhood tumor neuroblastoma. Here we investigate six of the put...

EML4-ALK-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.

The identification of oncogenic genomic alterations is expected to facilitate the development of new molecularly targeted therapies for cancer. EML4 (echinoderm microtubule-associated protein-like 4)-...